Almost a third of people treated with the higher dose had a bodyweight reduction of more than 25%, and 83.4% of patients with prediabetes at the start of the trial had returned to normal blood sugar levels by the end of the trial, compared to 73.8% for the standard dose and 36.6% for the placebo group
Teams must maintain structured workflows, document each step, and reconcile cases promptly
Like headaches, it might be due to blood sugar level changes
The protocol was approved by the Central Adelaide Local Health Network Human Research Ethics Committee (reference number: 2021/HRE00130), and prospectively registered in the Australian New Zealand Clinical Trials Registry (ACTRN12621000878875)
doi: 10.1172/JCI186633 37 SuMSunLLiWLiuHLiuYWeiYet al
Scientific studies have shown that tirzepatides dual GLP-1 and GIP action makes it more potent than semaglutides single GLP-1 action